JP2022509017A5 - - Google Patents

Info

Publication number
JP2022509017A5
JP2022509017A5 JP2021523752A JP2021523752A JP2022509017A5 JP 2022509017 A5 JP2022509017 A5 JP 2022509017A5 JP 2021523752 A JP2021523752 A JP 2021523752A JP 2021523752 A JP2021523752 A JP 2021523752A JP 2022509017 A5 JP2022509017 A5 JP 2022509017A5
Authority
JP
Japan
Application number
JP2021523752A
Other languages
Japanese (ja)
Other versions
JPWO2020095248A5 (https=
JP2022509017A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2019/059585 external-priority patent/WO2020095248A1/en
Publication of JP2022509017A publication Critical patent/JP2022509017A/ja
Publication of JPWO2020095248A5 publication Critical patent/JPWO2020095248A5/ja
Publication of JP2022509017A5 publication Critical patent/JP2022509017A5/ja
Priority to JP2024076832A priority Critical patent/JP2024097924A/ja
Pending legal-status Critical Current

Links

JP2021523752A 2018-11-07 2019-11-07 抗ptk7免疫細胞癌療法 Pending JP2022509017A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024076832A JP2024097924A (ja) 2018-11-07 2024-05-09 抗ptk7免疫細胞癌療法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862756638P 2018-11-07 2018-11-07
US62/756,638 2018-11-07
US201962910586P 2019-10-04 2019-10-04
US62/910,586 2019-10-04
PCT/IB2019/059585 WO2020095248A1 (en) 2018-11-07 2019-11-07 Anti-ptk7 immune cell cancer therapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024076832A Division JP2024097924A (ja) 2018-11-07 2024-05-09 抗ptk7免疫細胞癌療法

Publications (3)

Publication Number Publication Date
JP2022509017A JP2022509017A (ja) 2022-01-20
JPWO2020095248A5 JPWO2020095248A5 (https=) 2022-11-15
JP2022509017A5 true JP2022509017A5 (https=) 2022-11-15

Family

ID=68582072

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021523752A Pending JP2022509017A (ja) 2018-11-07 2019-11-07 抗ptk7免疫細胞癌療法
JP2024076832A Pending JP2024097924A (ja) 2018-11-07 2024-05-09 抗ptk7免疫細胞癌療法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024076832A Pending JP2024097924A (ja) 2018-11-07 2024-05-09 抗ptk7免疫細胞癌療法

Country Status (15)

Country Link
US (3) US20210290678A1 (https=)
EP (1) EP3877421A1 (https=)
JP (2) JP2022509017A (https=)
KR (1) KR20210092236A (https=)
CN (1) CN112955472A (https=)
AU (1) AU2019374523A1 (https=)
BR (1) BR112021008083A2 (https=)
CA (1) CA3118830A1 (https=)
CO (1) CO2021005471A2 (https=)
IL (1) IL282532A (https=)
MX (1) MX2021005400A (https=)
PH (1) PH12021551047A1 (https=)
SG (1) SG11202104631SA (https=)
WO (1) WO2020095248A1 (https=)
ZA (1) ZA202102745B (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115894696A (zh) * 2021-08-18 2023-04-04 和迈生物科技有限公司 抗ptk7单域抗体及其应用
WO2023084399A1 (en) * 2021-11-09 2023-05-19 Crispr Therapeutics Ag Genetically engineered immune cells expressing masked chimeric antigen receptors specific to protein tyrosine kinase 7
IL315366A (en) * 2022-03-23 2024-11-01 Synaffix Bv Antibody pairs for targeting PTK7-expressing tumors
AU2023272589A1 (en) * 2022-05-17 2025-01-09 Arsenal Biosciences, Inc. Systems of engineered receptors targeting psma and ca9
US20260078201A1 (en) * 2022-09-06 2026-03-19 Uif (University Industry Foundation), Yonsei University Anti-ptk7 antibody, and use thereof
WO2024151784A1 (en) * 2023-01-10 2024-07-18 Expression Therapeutics, Llc Engineered t cells
KR20250158048A (ko) 2023-03-03 2025-11-05 아스널 바이오사이언시스, 인크. Psma 및 ca9을 표적으로 하는 시스템
EP4684212A1 (en) * 2023-03-22 2026-01-28 Agilent Technologies, Inc. Immunohistochemistry (ihc) ptk7 scoring protocols and methods for aiding cancer treatments
CN117085134A (zh) * 2023-07-19 2023-11-21 浙江大学 Ptk7抑制剂在制备预防或治疗肝癌的药物中的用途
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof
US12534529B1 (en) 2024-11-19 2026-01-27 Solve Therapeutics, Inc. PTK7-binding proteins

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US6534055B1 (en) 1988-11-23 2003-03-18 Genetics Institute, Inc. Methods for selectively stimulating proliferation of T cells
US5858358A (en) 1992-04-07 1999-01-12 The United States Of America As Represented By The Secretary Of The Navy Methods for selectively stimulating proliferation of T cells
US6905680B2 (en) 1988-11-23 2005-06-14 Genetics Institute, Inc. Methods of treating HIV infected subjects
US7175843B2 (en) 1994-06-03 2007-02-13 Genetics Institute, Llc Methods for selectively stimulating proliferation of T cells
US6692964B1 (en) 1995-05-04 2004-02-17 The United States Of America As Represented By The Secretary Of The Navy Methods for transfecting T cells
US7067318B2 (en) 1995-06-07 2006-06-27 The Regents Of The University Of Michigan Methods for transfecting T cells
GB9710807D0 (en) 1997-05-23 1997-07-23 Medical Res Council Nucleic acid binding proteins
GB9710809D0 (en) 1997-05-23 1997-07-23 Medical Res Council Nucleic acid binding proteins
US6140081A (en) 1998-10-16 2000-10-31 The Scripps Research Institute Zinc finger binding domains for GNN
US6534261B1 (en) 1999-01-12 2003-03-18 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
US6453242B1 (en) 1999-01-12 2002-09-17 Sangamo Biosciences, Inc. Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites
US6797514B2 (en) 2000-02-24 2004-09-28 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US6867041B2 (en) 2000-02-24 2005-03-15 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
CA2406864A1 (en) 2000-02-24 2001-08-30 Life Technologies Corporation Simultaneous stimulation and concentration of cells
JP2002060786A (ja) 2000-08-23 2002-02-26 Kao Corp 硬質表面用殺菌防汚剤
US20040224385A1 (en) 2001-08-20 2004-11-11 Barbas Carlos F Zinc finger binding domains for cnn
US7888121B2 (en) 2003-08-08 2011-02-15 Sangamo Biosciences, Inc. Methods and compositions for targeted cleavage and recombination
US7972854B2 (en) 2004-02-05 2011-07-05 Sangamo Biosciences, Inc. Methods and compositions for targeted cleavage and recombination
EA017812B1 (ru) * 2005-12-08 2013-03-29 Медарекс, Инк. Выделенное моноклональное антитело или его антигенсвязывающий участок, которые связываются с протеинтирозинкиназой 7 ( ptk7) человека, и их применение
HUE041436T2 (hu) 2009-12-10 2019-05-28 Univ Minnesota Tal-effektor-közvetített DNS-módosítás
SA112330278B1 (ar) 2011-02-18 2015-10-09 ستيم سينتركس، انك. مواد ضابطة جديدة وطرق للاستخدام
US11041021B2 (en) * 2014-05-23 2021-06-22 University Of Florida Research Foundation, Incorporated Car based immunotherapy
TWI805109B (zh) * 2014-08-28 2023-06-11 美商奇諾治療有限公司 對cd19具專一性之抗體及嵌合抗原受體
WO2016069282A1 (en) 2014-10-31 2016-05-06 The Trustees Of The University Of Pennsylvania Altering gene expression in modified t cells and uses thereof
WO2017172981A2 (en) * 2016-03-29 2017-10-05 University Of Southern California Chimeric antigen receptors targeting cancer
NZ750256A (en) 2016-08-03 2026-02-27 Dipersio John F Gene editing of car-t cells for the treatment of t cell malignancies with chimeric antigen receptors
MX2020004185A (es) * 2017-09-27 2021-01-08 Univ Southern California Nuevas plataformas para coestimulacion, nuevos diseños car y otras mejoras para terapia celular adoptiva.
TW202208412A (zh) * 2020-05-06 2022-03-01 瑞士商Crispr治療公司 對酪胺酸蛋白激酶樣7(ptk7)特異的經掩蔽的嵌合抗原受體和表現其的免疫細胞

Similar Documents

Publication Publication Date Title
BR112019017762A2 (https=)
BR112021017339A2 (https=)
BR112021018450A2 (https=)
BR112021017637A2 (https=)
BR112021017892A2 (https=)
BR112021017782A2 (https=)
BR112021016821A2 (https=)
BR112021017939A2 (https=)
BR112021017738A2 (https=)
BR112021016996A2 (https=)
BR112021008711A2 (https=)
BR112019016141A2 (https=)
BR112021017728A2 (https=)
AU2020104490A5 (https=)
BR112021013944A2 (https=)
BR112021018452A2 (https=)
BR112021017703A2 (https=)
BR112021018102A2 (https=)
BR112019016142A2 (https=)
BR112019016138A2 (https=)
BR112021017732A2 (https=)
BR112021017234A2 (https=)
BR112021017355A2 (https=)
BR112021018168A2 (https=)
BR112021018093A2 (https=)